v3.25.4
Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Redeemable Noncontrolling Interest
Class A Common Stock
Class B Common Stock
Common Stock
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total vTv Therapeutics Inc Stockholders’ Equity (Deficit)
Noncontrolling Interest
Beginning balance at Dec. 31, 2022   $ 16,579                  
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss   (5,716)                  
Change in redemption value of noncontrolling interest $ (4,732) (4,732)                  
Ending balance at Dec. 31, 2023   6,131                  
Beginning balance, shares (in shares) at Dec. 31, 2022           2,084,973 577,349        
Beginning balance at Dec. 31, 2022 (10,740)         $ 21 $ 6 $ 254,757 $ (265,524) $ (10,740)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (20,250)               (20,250) (20,250)  
Share-based compensation 1,578             1,578   1,578  
Change in redemption value of noncontrolling interest 4,732               4,732 4,732  
Change in redemption value of noncontrolling interest (4,732) (4,732)                  
Net loss attributable to noncontrolling interest (5,716)                    
Ending balance, shares (in shares) at Dec. 31, 2023           2,084,973 577,349        
Ending balance at Dec. 31, 2023 (24,680)         $ 21 $ 6 256,335 (281,042) (24,680) $ 0
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Change in redemption value of noncontrolling interest (214)               (214) (214)  
Net loss attributable to redeemable noncontrolling interest [1]   (1,085)                  
Issuance of common stock upon exercise of stock options   214                  
Reclassification of redeemable noncontrolling interest to permanent equity (See Note 10) 5,260 (5,260)                 5,260
Ending balance at Dec. 31, 2024   0                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (18,462)               (18,462) (18,462)  
Share-based compensation 2,757             2,757   2,757  
Change in redemption value of noncontrolling interest (3,158)                   (3,158)
Change in redemption value of noncontrolling interest (214)               (214) (214)  
Reclassification of redeemable noncontrolling interest to permanent equity (See Note 10) 5,260 (5,260)                 5,260
Issuance of Class A common stock and pre-funded warrants, net offering costs (in shares)           347,884          
Issuance of common shares and equity classified warrants, net of offering costs 50,335         $ 3   50,332   50,335  
Issuance of Class A Common Stock under ATM offering (in shares)           179,400          
Issuance of Class A Common Stock under ATM offering 2,463         $ 2   2,461   2,463  
Net loss attributable to noncontrolling interest (4,243)                    
Ending balance, shares (in shares) at Dec. 31, 2024     3,938,654 577,349   2,612,257 577,349        
Ending balance at Dec. 31, 2024 14,301         $ 26 $ 6 311,885 (299,718) 12,199 2,102
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Change in redemption value of noncontrolling interest 0                    
Reclassification of redeemable noncontrolling interest to permanent equity (See Note 10) (51)             (51)   (51)  
Ending balance at Dec. 31, 2025   $ 0                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (26,974)               (26,974) (26,974)  
Share-based compensation 3,775             3,775   3,775  
Change in redemption value of noncontrolling interest $ 0                    
Issuance of common stock upon exercise of stock options (in shares) 21,355         1,336          
Issuance of common stock upon exercise of stock options $ 16             16   16  
Reclassification of redeemable noncontrolling interest to permanent equity (in shares)           4,258          
Reclassification of redeemable noncontrolling interest to permanent equity (See Note 10) (51)             (51)   (51)  
Issuance of Class A common stock and pre-funded warrants, net offering costs (in shares)           682,018          
Issuance of common shares and equity classified warrants, net of offering costs 77,476         $ 7   77,469   77,476  
Issuance of common stock - warrants exercised (in shares)           61,677          
Conversion of Class B Common Stock to Class A Common Stock (in shares)         577,108   (577,108)        
Conversion of Class B Common Stock to Class A Common Stock 0         $ 6 $ (6)        
Reclassification of noncontrolling interest to additional paid-in capital 0             (2,004)   (2,004) 2,004
Net loss attributable to noncontrolling interest (4,106)                   (4,106)
Ending balance, shares (in shares) at Dec. 31, 2025     2,612,257 241   3,938,654 241        
Ending balance at Dec. 31, 2025 $ 64,437         $ 39 $ 0 $ 391,090 $ (326,692) $ 64,437 $ 0
[1]
(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 10)